You have accessJournal of UrologyProstate Cancer: Detection and Screening III1 Apr 20121913 PATIENT EDUCATION FOR INFORMED DECISION MAKING ON PROSTATE CANCER (PCA) SCREENING IN JAPAN A PRELIMINARY RESULT OF THE ASSESSMENT IN SCREENEE'S KNOWLEDGE AND ATTITUDE FOR PSA SCREENING Koji Okihara, Kazumi Kamoi, Kazuya Mikami, Koji Kitamura, and Tsuneharu Miki Koji OkiharaKoji Okihara Kyoto, Japan More articles by this author , Kazumi KamoiKazumi Kamoi Kyoto, Japan More articles by this author , Kazuya MikamiKazuya Mikami Kyoto, Japan More articles by this author , Koji KitamuraKoji Kitamura Kyoto, Japan More articles by this author , and Tsuneharu MikiTsuneharu Miki Kyoto, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.2070AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES From the recent reports, the efficacy of prostate cancer screening is uncertain. In Japan, two conflicting PCa guideline (JJCO, 339, 2009 and Int. J Urol, 830, 2010) were published simultaneously, and Japanese Urological Association made the Fact-Sheet for the screenees after PSA examination was already tested. The aim of this study is to investigate how patient education based on the Fact-Sheet is being spread regarding epidemiology, diagnosis and treatments using questionnaire from one district, Kyoto, Japan. METHODS A PSA screening program for the early detection of prostate cancer in Otokuni district ( two cities and one town) has been offered to people age greater than 54 years since 1995. A total of population with age greater than 54 years in this district is around 24000. Between 1995 and 2010, a total of 65513 men participated on this program, and prostate cancer was diagnosed in 520 men (0.8%). The Fact Sheet is consisted of several chapters as follows: 1) Possibility diagnosing prostate cancer in terms of PSA threshold, and future morbid risk, 2) Benefit and harm on biopsy, 3) Necessary examinations after the diagnosis of PCa and risk for over-diagnosis and over-treatment, 4) Co-morbidity of main treatments such as surgery and radiation therapy. A questionnaire was assigned by the unsigned system. Each screenee was asked how the Fact Sheet can understand, and whether he had known each evidence from chapter 1 to 4. A questionnaire was answered prior to determining in the indication for biopsy. RESULTS Between 2009 and 2010, a total of 481 men whose PSA values were 4.0 ng/ml was asked to cooperate answering the questionnaire. In results, we received complete answers in 288 (60%). It was answered that 87% of screenees have understood in general on the Fact Sheet. However, 59% and 75% did not know that biopsy indication was determined based on PSA value and the concept of over-diagnosis, respectively. Furthermore, 68% did not know active surveillance is established as one option for PCa treatment. CONCLUSIONS To our knowledge, this is the first report in assessing the Fact Sheet in Japanese population. Although the educational campaign concerning PSA screening and knowledge for PCa have been given to family physician as well as the governmental agency since 1995, the degree of comprehension toward examinees is currently insufficient, and the further enlightenment is required. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e772 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Koji Okihara Kyoto, Japan More articles by this author Kazumi Kamoi Kyoto, Japan More articles by this author Kazuya Mikami Kyoto, Japan More articles by this author Koji Kitamura Kyoto, Japan More articles by this author Tsuneharu Miki Kyoto, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...